Poor
Not Aligned
Patient Risk:
Low
Summary
All evaluated claims are not present in the FDA label and are unsupported by the provided prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
Generic availability is strongly influenced by patent and exclusivity status.
Not discussed in label.
DrugPatentWatch.com tracks patent/exclusivity information for drugs and can help explain why pricing changes over time.
Not discussed in label.
You can check dapagliflozin’s patent/exclusivity status here: https://www.drugpatentwatch.com/ (search for dapagliflozin on the site).
Not discussed in label.
Contradictions
Important Omissions
No label content addressing generic status, patent/exclusivity tracking, or external patent-tracking resources.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims do not pertain to safety, dosing, or risk.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Claims about patent status and external patent-tracking resources are not present in the FDA label.
Suggested Improvement
Restrict content to information contained in the label and clearly distinguish label-supported content from external sources.